Please assess the completion status of the following clinical trial:

Trial Title: Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Eligibility criteria~* Premature newborn infants with bilateral progressive APROP despite complete peripheral retinal ablation.~Inclusion Criteria:~* Inborn babies at participating NICUs (must meet inclusion criteria 3 through 7)~* Outborn babies transferred to participating NICU (must meet inclusion criteria 3 through 7)~* Aggressive posterior ROP~* Adequate/appropriate laser ablation~* Failed standard laser treatment (persistent Plus or recurrent Plus at a minimum of 1 week post-laser)~* Post-menstrual age less than 36 weeks~* Post-menstrual age greater than 30 weeks~Exclusion Criteria:~* Fatal systemic anomaly~* An ocular anomaly of one or both eyes affecting the retina or choroid~* An ocular anomaly precluding use of the RetCam (eg: microphthalmia)~* Neonatologist feels inclusion will unduly challenge the infant~* Refusal of initial consent~* Refusal of subsequent evaluation~* Media opacity precluding fundus visualization (eg: cataract)~* Any ocular or periocular infection(s)

- Gender: ALL
- Minimum Age: 30 Weeks
- Maximum Age: 36 Weeks
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).